Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Document Type
Journal Article
Publication Date
1-9-2018
Journal
Circulation
Volume
137
Issue
2
Inclusive Pages
119-129
DOI
10.1161/CIRCULATIONAHA.117.028268
Keywords
Aged; Albuminuria; Benzhydryl Compounds; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Glucosides; Hospitalization; Humans; Kidney; Male; Middle Aged; Prevalence; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome
APA Citation
Wanner, C., Lachin, J., Inzucchi, S., Fitchett, D., Mattheus, M., George, J., Woerle, H., Broedl, U., von Eynatten, M., & Zinman, B. (2018). Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.. Circulation, 137 (2). http://dx.doi.org/10.1161/CIRCULATIONAHA.117.028268
Peer Reviewed
1